drugset / Trial / NCT03759093
CURATE.AI Optimized Modulation for Multiple Myeloma
Phase 2/3
Unknown
20 enrolled
National University Hospital, Singapore
National University of Singapore · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
Clinical trial applying CURATE.AI, a Phenotypic Precision Medicine (PPM) platform, to Bortezomib, Thalidomide, Cyclophosphamide and Lenalidomide dosing in multiple myeloma patients to show improvement in response.
Timeline
- Start
- 2023-09-10
- Primary completion
- 2025-09-10
- Completion
- 2025-09-10
Publications
- Background Pantuck, A.J., Lee, D.K., Kee, T., Wang, P., Lakhotia, S., Silverman, M.H., Mathis, C., Drakaki, A., Belldegrun, A.S., Ho, C.M. and Ho, D., 2018. Modulating BET Bromodomain Inhibitor ZEN-3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE. AI, an Artificial Intelligence Platform. Advanced Therapeutics, 1(6), p.1800104.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 0.7 mg/m2 | Subcutaneous |
| Subject | Bortezomib | Small molecule | 1 mg/m2 | Subcutaneous |
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Subcutaneous |
| Subject | Cyclophosphamide | Other / unclassified | 100 mg | Oral |
| Subject | Cyclophosphamide | Other / unclassified | 300 mg | Oral |
| Subject | Cyclophosphamide | Other / unclassified | 500 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 5 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |
| Subject | Thalidomide | Other / unclassified | 50 mg | Oral |
| Subject | Thalidomide | Other / unclassified | 200 mg | Oral |
| Background | Dexamethasone | Small molecule | 40 mg | Oral |